NeuroBo Pharmaceuticals’ DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

June 22, 2024

https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-da-1726-demonstrated-superiority-in-weight-loss-retention-of-lean-body-mass-and-lipid-lowering-effects-compared-to-survodutide-in-pre-clinical-models-302179186.html

NeuroBo Pharmaceuticals’ DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
/PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,…
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-da-1726-demonstrated-superiority-in-weight-loss-retention-of-lean-body-mass-and-lipid-lowering-effects-compared-to-survodutide-in-pre-clinical-models-302179186.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.